| Date | Title | Description |
| 25.12.2024 | Preliminary Results of Qilu Pharmaceutical's Phase Ia Study on GPRC5D/CD3-Targeting Bispecific Antibody QLS32015 Unveiled at 2024 ASH Annual Meeting | JINAN, China, Dec. 25, 2024 /PRNewswire/ -- During the 66th Annual Meeting of the American Society of Hematology (ASH) held in San Diego from December 7 to 10, preliminary results from the first human trial of QLS32015, a novel anticancer d... |
| 12.12.2024 | KIND Presents Preclinical Results of AND017 in Animal Models of Sickle Cell Disease (SCD), Myelodysplastic Syndromes (MDS), and β-Thalassemia at the 66th American Society of Hematology Meeting and Exp... | SAN FRANCISCO, Dec. 12, 2024 /PRNewswire/ -- Kind Pharmaceutical ("Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC"), a clinical-stage biopharmaceutical company focused on developing innovative medicines to treat h... |
| 10.12.2024 | Cayuga's poly-P-SNP Complex Demonstrates >90% Shorter Bleeding Time and Nearly 60% Less Blood Loss After Severe Injury | -- Data on Novel Synthetic Short-Chain Polyphosphate (polyP) Complexed with Silica Nanoparticle (SNP) Presented at 66th ASH Annual Meeting --
These data are exciting because they show that the polyP-SNP complex has the potential to transfor... |
| 09.12.2024 | Strength in Numbers: How Resistance Training Transforms Lives for Multiple Myeloma Patients | In the battle against cancer, every weapon counts. For patients with multiple myeloma, a type of blood cancer, a new ally has emerged: resistance training. Researchers at Roswell Park Comprehensive Cancer Center have unveiled groundbreaking... |
| 09.12.2024 | Resistance Training Can Reduce Fatigue, Pain in Multiple Myeloma Patients, Roswell Park Team Shows | Jens Hillengass, MD, PhD and Janine Joseph, MS, MBA
Researchers from Roswell Park Comprehensive Cancer Center will present compelling findings showcasing significant benefits of resistance training for patients with multiple myeloma, in a t... |
| 08.12.2024 | Roswell Park Experts Report Insights on CAR T for Follicular Lymphoma, KEYNOTE-667 Combo in Hodgkin Lymphoma | Kara Kelly, MD, and Matthew Cortese, MD, MPH
The results of two important lymphoma studies led by experts at Roswell Park will be presented during oral abstract sessions this morning at the 66th annual meeting of the American Society of Hem... |
| 07.12.2024 | Keto diet metabolite may power up CAR T cells to kill cancer | SAN DIEGO – A simple dietary supplement may provide a new approach to boost CAR T cell function, according to a study from researchers in the Perelman School of Medicine at the University of Pennsylvania and Penn Medicine’s Abramson Cancer ... |
| 06.12.2024 | Cereno Scientific to present preclinical data for drug candidate CS585 at the ASH Annual Meeting and Exposition 2024 | Cereno Scientific to present preclinical data for drug candidate CS585 at the ASH Annual Meeting and Exposition 2024
Fri, Dec 06, 2024 08:00 CET Report this content
Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pione... |
| 06.11.2024 | CARsgen® to Present Zevor-cel, CT071 and CT0590 at ASH 2024 Annual Congress | SHANGHAI, Nov. 6, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the Comp... |
| 07.08.2024 | PeproMene Bio announced study demonstrating strong polyfunctionality of novel chimeric antigen receptor (CAR) T cells | Polyfunctionality correlates with a patient's remission lasting over 18 months with the CAR T cell therapy
IRVINE, Calif., Aug. 7, 2024 /PRNewswire/ -- PeproMene Bio, Inc., a clinical-stage biotech company developing novel therapies for can... |
| 01.08.2024 | Syndax Reports Second Quarter 2024 Financial Results and Provides Clinical and Business Update | – Axatilimab BLA in refractory chronic GVHD is under Priority Review; PDUFA action date of August 28, 2024 –
– Revumenib NDA in R/R KMT2Ar acute leukemia is being reviewed under RTOR; PDUFA action date of December 26, 2024 –
– Pivotal AUGME... |
| 31.07.2024 | Navigating the Future of Cancer Treatment and Cybersecurity: A Dual Perspective on Innovation | In the ever-evolving landscape of healthcare and technology, two recent developments stand out: Syndax Pharmaceuticals’ progress with revumenib and Exiger’s acquisition of aDolus. Both represent critical advancements in their respective fie... |
| 31.07.2024 | A New Dawn in Treatment: CNT201 and Revumenib Pave the Way for Hope | In the ever-evolving landscape of medical science, two recent developments shine like beacons of hope. Connext’s CNT201 for Dupuytren's contracture and Syndax’s revumenib for KMT2Ar acute leukemia are not just treatments; they represent the... |
| 29.07.2024 | Syndax Announces PDUFA Action Date Extension for Revumenib NDA for Relapsed or Refractory KMT2Ar Acute Leukemia | – New PDUFA action date of December 26, 2024 allows FDA additional time to complete their review –
WALTHAM, Mass., July 29, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an... |
| 18.06.2024 | Live from EHA 2024 | Ascentage Pharma Releases Updated Data of Lisaftoclax in Patients with R/R MM and AL Amyloidosis Highlighting Marked Improvement in ORR | SUZHOU, China and ROCKVILLE, Md., June 18, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced ... |
| 14.06.2024 | Syndax Presents Updated Positive Data from BEAT AML and AUGMENT-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress | - Data continue to support revumenib's potential to enhance current standard of care agents -
- 96% CRc (23 of 24 pts) observed in BEAT AML trial exploring revumenib in combination with venetoclax/azacitidine in newly diagnosed mNPM1 or KMT... |
| 15.02.2024 | Professional Education and Resources | Image
Jump to:
Project Socrates
Project Socrates is OCE's professional education and engagement effort. In 2023, the project launched a monthly newsletter, the OCE PULSE, for hematology/oncology fellows, early career faculty, and anyone int... |
| 12.12.2023 | New sickle cell disease CRISPR treatments can’t make up for the shortage of adult hematologists | After decades of limited progress in the treatment of sickle cell disease (SCD), both patients and physicians are on the verge of monumental change. On Friday, the Food and Drug Administration approved Vertex/CRISPR Therapeutics’ Casgevy an... |
| 02.11.2023 | Faron to present data from BEXMAB study at ASH | Faron to present data from BEXMAB study at ASH
Thu, Nov 02, 2023 14:00 CET Report this content
Faron to present Phase 1/2 data from BEXMAB Study of Bexmarilimab in Combination with Standard of Care in Myeloid Malignancies at the 65th Americ... |
| 30.10.2023 | Health | For people with sickle cell disease, ERs can mean life-threatening waits | Sara Hutchinson | (TNS) KFF Health News
Heather Avant always dresses up when she goes to the emergency room.
“I’ve been conditioned to act and behave in a very specific way,” said Avant. “I try to do my hair. I make sure I shower, have nice... |
| 21.12.2022 | Specialized centers can help realign the U.S.’s moral compass for sickle cell disease | Even as the United States has made commitments to health as a human right and reversing health disparities and has invested significantly in orphan diseases, it continues to overlook sickle cell disease (SCD), the most common inherited bloo... |
| 11.11.2022 | Sobi to present new data at the ASH 2022 Annual Meeting | Sobi to present new data at the ASH 2022 Annual Meeting
Fri, Nov 11, 2022 09:00 CET Report this content
Sobi® will present new data at the 64th Annual Meeting of the American Society of Hematology (ASH) taking place from 10 to 13 December 2... |
| 03.11.2022 | I-Mab Announces Two Poster Presentations of CD47 Antibody Lemzoparlimab at ASH 2022 | GAITHERSBURG, MD. and SHANGHAI, Nov. 3, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today... |
| 01.06.2022 | 'Frailty Exams' for Older Cancer Patients May Not Need Office Visit | WEDNESDAY, June 1, 2022 (HealthDay News) -- Frailty exams are recommended for older adults who have blood cancer, and new research shows they can be done virtually, not just in person.
While the screenings are typically conducted at a clini... |
| 15.12.2021 | Oncolytics Biotech® Announces the Presentation of Preclinical Data Demonstrating the Synergistic Anti-Leukemic Effects of Pelareorep Combined with Azacitidine at the 2021 American Society of Hematolog... | - Treatment with intravenous pelareorep plus azacitidine reduced tumor burden
- Treatment with pelareorep and azacitidine dramatically upregulated multiple genes known to drive anti-cancer immune responses
SAN DIEGO and CALGARY, AB, Dec. 15... |
| 14.12.2021 | Antengene Presents Results of Phase 1b TOUCH Trial of Selinexor for the Treatment of T and NK-Cell Lymphoma at the 2021 American Society of Hematology (ASH) Annual Meeting | SHANGHAI and HONG KONG, Dec. 14, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative global biopharmaceutical company dedicated to discovering, developing and commercializing first... |
| 13.12.2021 | Affimed Shares Preclinical Data on Innate Cell Engagers AFM28 and AFM13 at the 63rd American Society of Hematology Annual Meeting and Exposition | AFM28 effectively induces depletion of leukemic cells in patient bone marrow samples and demonstrates the anticipated good safety profile and pharmacologic activity in cynomolgus monkeysPre-complexing AFM13 with NK cells generates CAR-like ... |
| 11.12.2021 | Gilead, Bristol jaw over the superiority of rival CAR-T treatments for blood cancer | Competing, bespoke CAR-T cell therapies from Gilead Sciences and Bristol Myers Squibb have each demonstrated additional benefit for patients with B-cell lymphoma at an earlier stage of treatment than they’re used for currently. But is one b... |
| 19.11.2021 | Treating Patients Beyond Borders - Antengene Successfully Hosted Its First R&D Day | - Highlighted R&D Strategy and Broad Pipeline of 15 Programs including 10 with Worldwide Rights
- ATG-010's First Approval in Asia transforms Antengene into a Commercial Entity, 10 Studies in ATG-010 being Conducted in Mainland China
- ... |
| 12.11.2021 | Aptose Reports Results for the Third Quarter 2021 | - Conference call and webcast at 5:00 pm ET today -
- HM43239, myeloid kinome inhibitor with clinically validated activity added to pipeline -
- HM43239 phase 1/2 study in AML advances to 200 mg dose -
- Luxeptinib phase 1a/b studies in AML... |
| 09.11.2021 | Antengene to Release Preliminary Results of Selinexor for the Treatment of Peripheral T-Cell Lymphoma and NK/T-Cell Lymphoma at the 2021 ASH Annual Meeting | SHANGHAI and HONG KONG, Nov. 9, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative global biopharmaceutical company dedicated to discovering, developing and commercializing first-... |
| 04.11.2021 | Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2021 | • Sponsored programs at ASH 2021 - preliminary clinical data to be presented at ASH 2021 for product candidate UCART22 and preclinical data from Cellectis gene therapy product candidate TALGlobin01
• Partnered programs at ASH 2021 – ALPHA2 ... |
| 04.11.2021 | Sobi to present new data at the ASH 2021 Annual Meeting | Sobi to present new data at the ASH 2021 Annual Meeting Thu, Nov 04, 2021 15:35 CET
Sobi™ will present new data at the 63rd Annual Meeting of the American Society of Hematology (ASH) taking place from 11-14 December 2021. Sobi’s commitment ... |
| 04.11.2021 | Adicet Announces Trials in Progress Poster Presentation for ADI-001 at 2021 ASH Annual Meeting | MENLO PARK, Calif. and BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today... |
| 04.11.2021 | Affimed Announces Poster Presentations at the 63rd American Society of Hematology Annual Meeting and Exposition and Company-sponsored Event on AFM13 | A poster presentation featuring preclinical data on AFM28, a novel Innate Cell Engager developed for treatment of Acute Myeloid Leukemia and other CD123+ myeloid malignancies
A poster presentation on AFM13 precomplexed NK cells that maintai... |
| 01.04.2021 | Sickle Cell Disease Association of America, Inc. Launches New Educational Materials to Support Children’s Blood Transfusion | We appreciate that Hemanext has stepped up to help us fill this information need and make a difference breaking the sickle cycle. SCDAA President and CEO Beverley Francis-Gibson
HANOVER, Md. and LEXINGTON, Mass. (PRWEB) April 01, 2021
Sickl... |
| 08.12.2020 | Researchers Trace the Origin of Blood Cancer to Early Childhood, Decades before Diagnosis | |
| 04.12.2020 | New Studies Call Attention to Effects of Structural Inequities on Health in America | |
| 04.12.2020 | Clinical Trials Offer Opportunities to Change Practice to Improve Prevention and Treatment of Blood Disorders | |
| 06.12.2016 | Antibody shows dramatic post-transplant benefit in animal model | Antibody shows dramatic post-transplant benefit in animal model
06-12-2016
Kymab's new therapeutic antibody for autoimmune diseases, KY1005, shows potential for improvement in post-transplant survival in an animal model of Graft-versus-Host... |
| 05.12.2016 | Can Alnylam rise from the ASHes? | Now in San Diego, California, for the 58th American Society of Hematology (ASH) meeting, Alnylam desperately needs to change the conversation.
So what’s new? Pushkal Garg, Alnylam’s SVP of clinical development, met with MedCity News at ASH ... |
| 17.10.2016 | Celgene Acquires Biotech Startup EngMab | |
| 22.04.2014 | ProNAi Therapeutics Closes on $59.5M to Advance Cancer Drug | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
ProNAi Therapeutics, a Plymouth, MI-based developer of novel nucleic acid treatments targeting cancer and other genetic diseases, said this week that it has closed a Series D ... |
| 07.01.2014 | ProNAi Announces Progress on Its Novel Cancer-Fighting Drug | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
Mina Sooch, Detroit Xconomist and president and CEO of ProNAi Therapeutics, says 2013 was a landmark year for the biotech startup based in Plymouth, MI. ProNAi, which was spun... |
| 11.12.2013 | Apprennet awarded $150K Science Foundation grant [Startup Roundup] | WHO’S GETTING FUNDED?
Apprennet, an online learning startup, was awarded a $150,000 National Science Foundation grant to study whether or not teacher participation on their platform affects teacher effectiveness, said cofounder Emily Foote.... |
| 29.03.2012 | Basketball’s influence on stem cell treatments in sports medicine | Dragoo said in a phone interview that the publicity has actually had a negative impact on the development of clinically proven stem cell therapies for orthopedic medicine and how it is perceived. “Because of this market pressure, private cl... |
| - | Can Alnylam rise from the ASHes? | October was a bad month for Alnylam. Its shares plunged almost 50 percent after it abruptly scrapped its Phase 3 candidate revusiran, citing a disproportionate number of deaths in the active arm of the trial.
It was a major blow for the dou... |
| - | Oncopeptides to Highlight Data from Melflufen Clinical Program in Multiple Myeloma and AL Amyloidosis in Six Presentations at ASH Annual Meeting 2019 | A wide range of clinical and preclinical data for melflufen in both multiple myeloma and AL amyloidosis will be presented at the ASH annual meeting. Two key data sets that will be presented are;
“The acceptance of six abstracts from our ro... |
| - | Basketball’s influence on stem cell treatments in sports medicine | As the basketball frenzy that accompanies March Madness draws to the fever pitch of the Final Four, it brings to mind that basketball is a high contact sport. A quick peek at the NBA injured list reveals a catalog of breaks and tears that a... |
